[1]张璇,姜睿斌,张晓菊,等.地黄配伍玄参对糖尿病肾病大鼠微循环障碍的影响[J].西部中医药,2023,36(10):31-34.[doi:10.12174/j.issn.2096-9600.2023.10.06]
　ZHANG Xuan,JIANG Ruibin,ZHANG Xiaoju,et al.Effects of Dihuang Compatible with Xuanshen on Microcirculatory Disorders in Diabetic Nephropathy Rats[J].Western Journal of Traditional Chinese Medicine,2023,36(10):31-34.[doi:10.12174/j.issn.2096-9600.2023.10.06]
点击复制

地黄配伍玄参对糖尿病肾病大鼠微循环障碍的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年10期
页码:
31-34
栏目:
出版日期:
2023-10-15

文章信息/Info

Title:
Effects of Dihuang Compatible with Xuanshen on Microcirculatory Disorders in Diabetic Nephropathy Rats
作者:
张璇1,2, 姜睿斌2, 张晓菊2, 董晓静2, 薛松妍2, 李锋2
1.陕西中医药大学，陕西 咸阳 714000
2.空军（第四）军医大学第一附属西京医院，陕西 西安 710032
Author(s):
ZHANG Xuan1,2, JIANG Ruibin2, ZHANG Xiaoju2, DONG Xiaojing2, XUE Songyan2, LI Feng2
1.Shaanxi University of Chinese Medicine, Xianyang 714000, China
2.Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China
关键词:
糖尿病肾病; 地黄玄参配伍; 血糖; 血脂; 肾功能
Keywords:
diabetic nephropathy; compatible with; blood glucose; blood lipid; renal function
分类号:
R285.5
DOI:
10.12174/j.issn.2096-9600.2023.10.06
文献标志码:
A
摘要:
目的研究地黄玄参配伍对糖尿病肾病大鼠肾脏的保护机制。 方法选择40只SD雄性大鼠，随机选取7只作为空白对照组，其余22只采用高脂饲料喂养联合链脲佐菌素腹腔注射构建糖尿病肾病大鼠模型。造模成功后，随机分为模型组（10只）、地黄玄参组（6只）、二甲双胍组（6只）；观察各组大鼠治疗前后一般情况，并测定治疗后各组大鼠体质量、血糖、血肌酐、血尿素氮及血脂的变化。 结果与空白对照组比较，模型组体质量下降，血糖、血肌酐、血尿素氮、血脂均明显升高；与空白对照组相比，模型组及给药组的体质量均降低（P＜0.001），血糖、血肌酐、血尿素氮、血脂均升高（P＜0.05）；与模型组相比，给药组体质量升高（P＜0.05）；给药组间体质量比较，差异无统计学意义（P＞0.05）；血糖、甘油三酯（triglyceride，TG）、总胆固醇（total cholesterol，TC）、肌酐（serum creatinine，SCr）、尿素氮及肾脏指数给药组均低于模型组（P＜0.05），给药组间比较，差异无统计学意义（P＞0.05）。 结论地黄配伍玄参能够纠正实验性糖尿病肾病大鼠的糖、脂代谢紊乱，减轻微循环障碍，保护肾功能，减轻糖尿病肾病大鼠肾损害。
Abstract:
ObjectiveTo study the mechanism of compatibility of Dihuang and Xuanshen protecting the kidney in diabetic nephropathy (DN) rats. MethodsAfter choosing forty SD male rats, seven were randomly selected as blank control group, the remaining 22 rats were given high-fat feed and intraperitoneal injection of streptozotocin (STZ) so as to prepare DN rat models. After successful modeling, the rat models were randomized the model group (ten rats), the compatibility group (six rats) and melbine group (six rats); to observe general conditions of the rats in different groups before and after the treatment, and detect the changes of body mass, blood glucose, blood creatinine, blood urea nitrogen (BUN) and blood lipid of the rats in different groups after the treatment. ResultsCompared with blank control group, body mass decreased while the levels of blood glucose, blood creatinine, BUN and blood lipid obviously increased in the model group; compared with blank control group, body mass lowered in the model group and the medication group (P<0.01), the levels of blood glucose, blood creatinine, BUN and blood lipid lifted (P<0.05); body mass elevated in the medication group than the model group (P<0.05); the difference had no statistical meaning in body mass between the medication groups (P>0.05); the levels of blood glucose, TG, TC, SCr, BUN and kidney indexes of the medication group were lower than these of the model group (P<0.05), the difference had no statistical meaning between the medication groups (P>0.05). ConclusionThe compatibility of Dihuang with Xuanshen could correct glucose and lipid metabolism disorders in rats with experimental DN, relieve microcirculatory disorders, protect renal function and alleviate renal damage.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):62.
[3]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(10):77.
[4]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(10):96.
[5]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):68.
[8]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):1.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(10):96.

备注/Memo

备注/Memo:
张璇（1993—），女，硕士学位。研究方向：中医药防治肾病效应机制与临床评价。国家自然科学基金（81273622）。
更新日期/Last Update: 1900-01-01